Pan L, Li J, Xu Q, Gao Z, Yang M, Wu X
Medicine (Baltimore). 2024; 103(24):e38508.
PMID: 38875362
PMC: 11175886.
DOI: 10.1097/MD.0000000000038508.
You S, Gong C, Li Y, Xie Y, Li Y, Zhao Y
Front Endocrinol (Lausanne). 2023; 14:1270453.
PMID: 37881502
PMC: 10595148.
DOI: 10.3389/fendo.2023.1270453.
Chaudhary L, Jorns J, Sun Y, Cheng Y, Kamaraju S, Burfeind J
Breast Cancer Res Treat. 2023; 201(3):387-396.
PMID: 37460683
PMC: 10795510.
DOI: 10.1007/s10549-023-07038-3.
Chaudhary L, Jorns J, Sun Y, Cheng Y, Kamaraju S, Burfeind J
Res Sq. 2023; .
PMID: 37066270
PMC: 10104267.
DOI: 10.21203/rs.3.rs-2777910/v1.
Abbate J, Arfuso F, Riolo K, Capparucci F, Brunetti B, Lanteri G
Animals (Basel). 2023; 13(6).
PMID: 36978627
PMC: 10044548.
DOI: 10.3390/ani13061086.
Epigenetic factors in breast cancer therapy.
Mathur R, Jha N, Saini G, Jha S, Shukla S, Filipejova Z
Front Genet. 2022; 13:886487.
PMID: 36212140
PMC: 9539821.
DOI: 10.3389/fgene.2022.886487.
Estrogen receptor-low breast cancer: Biology chaos and treatment paradox.
Yu K, Cai Y, Wu S, Shui R, Shao Z
Cancer Commun (Lond). 2021; 41(10):968-980.
PMID: 34251757
PMC: 8504145.
DOI: 10.1002/cac2.12191.
Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer.
Yao J, Deng K, Huang J, Zeng R, Zuo J
Front Pharmacol. 2020; 11:592912.
PMID: 33362547
PMC: 7758911.
DOI: 10.3389/fphar.2020.592912.
Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo.
Attalla S, Taifour T, Bui T, Muller W
Oncogene. 2020; 40(3):475-491.
PMID: 33235291
PMC: 7819848.
DOI: 10.1038/s41388-020-01560-0.
Estrogen Receptor Positive and Progesterone Receptor Negative Breast Cancer: the Role of Hormone Therapy.
Dembinski R, Prasath V, Bohnak C, Siotos C, Sebai M, Psoter K
Horm Cancer. 2020; 11(3-4):148-154.
PMID: 32519274
PMC: 10355243.
DOI: 10.1007/s12672-020-00387-1.
MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer.
Rahman M, Brane A, Tollefsbol T
Cells. 2019; 8(10).
PMID: 31597272
PMC: 6829616.
DOI: 10.3390/cells8101214.
Hypoxia differentially regulates estrogen receptor alpha in 2D and 3D culture formats.
Whitman N, Lin Z, Kenney R, Albertini L, Lockett M
Arch Biochem Biophys. 2019; 671:8-17.
PMID: 31163125
PMC: 6688900.
DOI: 10.1016/j.abb.2019.05.025.
Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data.
You S, Chae B, Eom Y, Yoo T, Kim Y, Kim J
J Breast Cancer. 2019; 21(4):415-424.
PMID: 30607163
PMC: 6310716.
DOI: 10.4048/jbc.2018.21.e53.
Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer.
Ballinger T, Meier J, Jansen V
Front Oncol. 2018; 8:308.
PMID: 30148117
PMC: 6095972.
DOI: 10.3389/fonc.2018.00308.
ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.
Zhang J, Zhou C, Jiang H, Liang L, Shi W, Zhang Q
Cell Death Dis. 2017; 8(4):e2732.
PMID: 28383555
PMC: 5477580.
DOI: 10.1038/cddis.2017.154.
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
Giuliano M, Hu H, Wang Y, Fu X, Nardone A, Herrera S
Clin Cancer Res. 2015; 21(17):3995-4003.
PMID: 26015514
PMC: 4558260.
DOI: 10.1158/1078-0432.CCR-14-2728.
Mechanisms of aromatase inhibitor resistance.
Ma C, Reinert T, Chmielewska I, Ellis M
Nat Rev Cancer. 2015; 15(5):261-75.
PMID: 25907219
DOI: 10.1038/nrc3920.
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.
Fu X, Osborne C, Schiff R
Breast. 2013; 22 Suppl 2:S12-8.
PMID: 24011769
PMC: 3808116.
DOI: 10.1016/j.breast.2013.08.001.
Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.
Zhang X, Mu X, Huang O, Xie Z, Jiang M, Geng M
PLoS One. 2013; 8(8):e72053.
PMID: 23991038
PMC: 3753350.
DOI: 10.1371/journal.pone.0072053.
Promoter hypermethylation of estrogen receptor alpha gene is correlated to estrogen receptor negativity in Iranian patients with sporadic breast cancer.
Izadi P, Noruzinia M, Karimipoor M, Karbassian M, Akbari M
Cell J. 2013; 14(2):102-9.
PMID: 23508069
PMC: 3584424.
